Page last updated: 2024-10-22

alosetron and Indigestion

alosetron has been researched along with Indigestion in 5 studies

alosetron : A pyrido[4,3-b]indole compound having a 5-methyl-1H-imidazol-4-ylmethyl group at the 2-position.

Research Excerpts

ExcerptRelevanceReference
"A total of 320 functional dyspepsia patients received placebo (n=81), or alosetron 0."9.09A dose-ranging, placebo-controlled, randomized trial of alosetron in patients with functional dyspepsia. ( Dukes, G; Heath, M; Kleoudis, C; Mangel, AW; Perschy, T; Saez, LR; Talley, NJ; Van Zanten, SV, 2001)
"A total of 320 functional dyspepsia patients received placebo (n=81), or alosetron 0."5.09A dose-ranging, placebo-controlled, randomized trial of alosetron in patients with functional dyspepsia. ( Dukes, G; Heath, M; Kleoudis, C; Mangel, AW; Perschy, T; Saez, LR; Talley, NJ; Van Zanten, SV, 2001)
", 2D6 and 2C19), and the effects of genetic polymorphisms in the promoter of the serotonin transporter protein, which influence the response to alosetron in patients with diarrhea-predominant irritable bowel syndrome."4.82Pharmacogenomics and functional gastrointestinal disorders. ( Camilleri, M, 2005)

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (80.00)29.6817
2010's1 (20.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Dance, A1
Camilleri, M3
Coulie, B1
Talley, NJ1
Van Zanten, SV1
Saez, LR1
Dukes, G1
Perschy, T1
Heath, M1
Kleoudis, C1
Mangel, AW1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Prospective, Randomized, Investigator Blinded, Controlled Trial to Evaluate the Effectiveness of Dietary Modification in Patients With Functional Dyspepsia[NCT02863822]0 participants (Actual)Interventional2016-09-30Withdrawn (stopped due to no patients enrolled)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

3 reviews available for alosetron and Indigestion

ArticleYear
Pharmacogenomics and functional gastrointestinal disorders.
    Pharmacogenomics, 2005, Volume: 6, Issue:5

    Topics: Carbolines; Colonic Diseases, Functional; Diarrhea; Dyspepsia; Gastrointestinal Agents; Humans; Mode

2005
Pharmacogenomics and serotonergic agents: research observations and potential clinical practice implications.
    Neurogastroenterology and motility, 2007, Volume: 19 Suppl 2

    Topics: Appetite Depressants; Carbolines; Cyclobutanes; Dyspepsia; Gastrointestinal Agents; Genetic Variatio

2007
New therapies for functional bowel diseases.
    Current gastroenterology reports, 2000, Volume: 2, Issue:5

    Topics: Carbolines; Colonic Diseases, Functional; Dyspepsia; Gastrointestinal Agents; Humans; Psychotherapy

2000

Trials

1 trial available for alosetron and Indigestion

ArticleYear
A dose-ranging, placebo-controlled, randomized trial of alosetron in patients with functional dyspepsia.
    Alimentary pharmacology & therapeutics, 2001, Volume: 15, Issue:4

    Topics: Administration, Oral; Adult; Carbolines; Dose-Response Relationship, Drug; Double-Blind Method; Dysp

2001

Other Studies

1 other study available for alosetron and Indigestion

ArticleYear
Transit time.
    Nature, 2016, 05-19, Volume: 533, Issue:7603

    Topics: Anti-Bacterial Agents; Biofeedback, Psychology; Carbolines; Colitis; Diet; Dysentery; Dyspepsia; Egy

2016